Targeted therapy for lung cancer: reviewing the cost and its effect on treatment decisions

摘要: SUMMARY  Novel targeted therapies that improve outcome in advanced lung cancer should be adopted. However, given the high costs of and companion molecular testing, affordability cost–effectiveness novel agents are growing relevance policy decisions. Incremental ratios excess US$200,000 per quality-adjusted life year have been described published literature evaluating currently approved agents. Differing willingness to pay thresholds different countries determine which will funded a healthcare system. Cost-containment strategies address testing drug acquisition need implemented. Drug manufacturers, payers oncologists shared responsibility ensure affordable accessible patients need.